

Thiamine supplementation in type 2 diabetes

Submission date 20/11/2009	Recruitment status No longer recruiting	☒ Prospectively registered ☐ Protocol
Registration date 04/01/2010	Overall study status Completed	☐ Statistical analysis plan ☐ Results
Last Edited 20/04/2017	Condition category Nutritional, Metabolic, Endocrine	☐ Individual participant data ☐ Record updated in last year

Plain English summary of protocol

Background and study aims

People with diabetes mellitus are at increased risk of developing heart disease and strokes. Thiamine is a vitamin that is needed by the body to regulate blood sugar levels and may also be involved in preventing heart disease. This study aims to see whether giving additional thiamine can reduce the risk of developing heart disease.

Who can participate?

This study is looking for 34 participants aged between 18 and 70 who are known to have type 2 diabetes.

What does the study involve?

This study will take place over a 5-month period and participants will need to attend for four visits each lasting about 2 hours. On the first visit you will need to undergo a routine physical examination and have an ECG (tracing of your heart). At each of the visits you will need to have fasted from the evening before, provide a sample of urine (to test for protein levels) and undergo blood tests (30 ml of blood) to check your kidneys, liver, blood fat levels, insulin sensitivity, thiamine levels, and diabetes control. We will then assess the function of the lining of the blood vessels using a probe that is applied to your fingertip (this is painless) attached to a specialised machine. We repeat the finger-probe test after administration of GTN spray under the tongue and again following administration of inhaled salbutamol via a spacer device. These medications are usually used for angina and asthma respectively and work by temporarily dilating the blood vessels. At the doses used in the study they have rare mild side effects which include transient headache and a metallic taste in the mouth. After the first visit you will be given either thiamine tablets to be taken once a day or a placebo (dummy) equivalent. You are to take these tablets for 8 weeks and then return for the same protocol of urine, blood and finger-probe testing as described above. You will then be given a minimum 2-week break before the same testing procedure will be repeated with a further 8-week administration of thiamine or placebo (whichever you did not receive the first time). The blood samples taken during the study will be stored for up to 12 months after completion of the study and may be analysed for other markers that may be related to circulatory disease.

What are the possible benefits and risks of participating?

The aim is to see whether thiamine can help reduce the risk of developing diseases such as heart attacks and stroke while also improving a persons general diabetic health. Therefore, although

the study will not specifically benefit your diabetic/medical care, the results may be beneficial in the care of many patients with diabetes in the future. The Food Standards Agency has shown that the oral administration of thiamine is safe and non-toxic. A small number of individuals may show an allergic response to lower doses but reports of these events are rare.

Where is the study run from?

The study will be run from Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust (UK).

When is the study starting and how long is it expected to run for?

The study ran from February 2010 to August 2011.

Who is funding the study?

All study funding is coming from internal departmental budgets.

Who is the main contact?

Dr Georgina Page

gljpage@gmail.com

Contact information

Type(s)

Scientific

Contact name

Prof Michael Cummings

Contact details

Academic Department of Diabetes and Endocrinology

Portsmouth Hospitals NHS Trust

Southwick Hill Road

Cosham

Portsmouth

United Kingdom

PO6 3LY

--

michael.cummings@porthosp.nhs.uk

Additional identifiers

Protocol serial number

PHT/2009/36

Study information

Scientific Title

Oral thiamine (Vitamin B1) supplementation in subjects with type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled crossover trial assessing biophysical markers of endothelial function, oxidant stress, insulin sensitivity and vascular inflammation

Study objectives

It is well known that people with type 2 diabetes are more prone to circulatory-related diseases (heart attack, stroke) when compared with individuals without diabetes. It is thought that this is related to problems with the function of the lining of blood vessels (endothelium), an increase in generalised inflammation within the blood vessels and various other factors including over-production of harmful by-products (oxidative stress). The changes in the endothelium that occur subsequently contribute to blocking of the arteries (atherosclerosis), which can lead to heart attack or stroke.

Similar mechanisms to those just described have been implicated in the development of other complications of type 2 diabetes such as kidney and eye disease as well as the development of type 2 diabetes itself. Traditional risk factors for this include smoking, raised cholesterol, excess weight and family history and these have all been extensively studied. However, despite modification of these risk factors the occurrence of these diabetes and these complications continues to rise and therefore further research is being done to look at other potential modifiable elements.

Thiamine is a water-soluble vitamin essential found naturally in raw foods. It is known that, despite a normal dietary intake of thiamine, people with diabetes have a lower level of thiamine in their blood compared to individuals without diabetes. It is an important regulator of glucose metabolism and some experimental studies have shown that thiamine may have a role in maintaining function of the endothelium.

This study aims to investigate whether thiamine supplementation will have benefits in the way of reducing inflammation, reducing formation of harmful by-products and improving the body's ability to use insulin.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Southampton B Research Ethics Committee (REC), 11/01/2010, ref: 09/H0504/137

Study design

Single-centre randomised placebo-controlled double-blind crossover trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Type 2 diabetes mellitus

Interventions

Thiamine (vitamin B1/thiamine hydrochloride) versus placebo. Thiamine is being given orally at a dose of 300 mg daily for 8 weeks.

Total duration of treatment: 8 weeks each for thiamine or placebo

Duration of follow-up: 18 weeks in which the participant is in the study

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

Thiamine

Primary outcome(s)

Change in VCAM-1 (vascular adhesion molecule-1) levels pre- and post-treatment (baseline and 8 weeks). This is a surrogate marker of vascular inflammation.

Key secondary outcome(s)

Measured at 8 weeks:

1. Measurement of endothelial dysfunction determined by the reflection index of the digital volume waveform using photoplethysmography
2. Measurement of insulin sensitivity (pancreatic B-cell function [HOMA-B] method)
3. Markers of oxidant stress (total antioxidant status [TAOS], lipid hydroperoxides [LHP], cyclic guanosine monophosphate [cGMP], glutathione [GSH]/oxidised glutathione [GSSG])
4. Markers of vascular inflammation (high sensitivity C-reactive protein [hsCRP] and albumin /creatinine ratio [ACR])
5. Glycaemic control (HbA1c, fructosamine)
6. Lipid parameters

Completion date

02/08/2011

Eligibility**Key inclusion criteria**

1. Individuals with a diagnosis of type 2 diabetes mellitus with a more than 30% chance of cardiovascular disease (ischaemic heart disease, cerebrovascular disease or peripheral vascular disease) over the next 10 years
2. HbA1c less than 10%
3. Between the ages of 18 and 75 years, either sex

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Key exclusion criteria

1. Established cardiovascular disease (ischaemic heart disease, cerebrovascular disease or peripheral vascular disease)
2. Allergy/intolerance to thiamine supplementation
3. Insulin treatment
4. Diuretic treatment
5. Current multivitamin/thiamine therapy
6. Abnormal thyroid function
7. Chronic excess alcohol consumption/impaired liver function (greater than 21 units per week in females, greater than 28 units per week in males; Department of Health Guidelines)

Date of first enrolment

01/02/2010

Date of final enrolment

02/08/2011

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

Academic Department of Diabetes and Endocrinology

Portsmouth

United Kingdom

PO6 3LY

Sponsor information

Organisation

Portsmouth Hospitals NHS Trust (UK)

ROR

<https://ror.org/009fk3b63>

Funder(s)

Funder type

Government

Funder Name

Portsmouth Hospitals NHS Trust (UK) - Academic Department of Diabetes and Endocrinology

Funder Name

Diabetes UK (UK) - in process of applying for a small grant

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
HRA research summary			28/06/2023	No	No